HTG EdgeSeq assays employ nuclease protection to measure RNA. Target-specific protection probes with universal priming sites (wings) hybridize to target transcripts and wingman (1). S1 nuclease is added to digest non-hybridized probes and RNA, resulting in a 1-to-1 ratios of probes and target RNAs (2).
After S1 nucleuse inactivation (3), the remaining probes are amplified with primers carrying sequencing adaptors and molecular barcodes (4). The resulting PCR products are purified, quantitated, and combined to make a sequencing ready library (5). HTG EdgeSeq assays do not require processing steps such as reverse transcription, adenylation, or adaptor ligation.
Steps 1 - 3 are fully automated on the HTG EdgeSeq system.
Our chemistry supports a wide variety of sample types, including formalin-fixed, paraffin-embedded (FFPE) samples.
Our expertly curated gene expression panels leverage the power and sensitivity of next-generation sequencing, allowing you to measure the expression levels of a few hundred genes to whole mRNA and miRNA transcriptome. Our breakthrough technology generates results from clinically relevant samples, such as formalin-fixed, paraffin-embedded (FFPE) tissue, to support biomarker discovery, drug targeting, and diagnostics development.
Develop profiles of human miRNA transcripts and evaluate gene regulation
Comprehensive characterization of genes associated with tumor biology
Analyze genes associated with immune response to infection and autoimmune disease
Analyze genes associated with Oncology, Immunology and Inflammation
Learn more about the HTG EdgeSeq Chemistry.
Page last updated April 21, 2022